Lucid Diagnostics News

Lucid Diagnostics (LUCD.US): The 2024 Q1 financial report achieved revenue of US$1.01 million, with a previous value of US$446,000 and an expected value of US$1.05 million; earnings per share were -0.21 dollars, previous value was -0.24 dollars, and expec

Lucid Diagnostics (LUCD.US): The 2024 Q1 financial report achieved revenue of US$1.01 million, with a previous value of US$446,000 and an expected value of US$1.05 million; earnings per share were -0.21 dollars, previous value was -0.24 dollars, and expected value was -0.27 dollars.

Zhitong FinanceMay 13 20:03

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)

TipRanksMay 13 23:50

Lucid Diagnostics | 10-Q: Quarterly report

SEC announcementMay 13 20:24 · Announcements

Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues To Deliver Results As We Drive Towards Expanded...

Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues

BenzingaMay 13 20:08

Lucid Diagnostics 1Q Loss $18.1M >LUCD

Lucid Diagnostics 1Q Loss $18.1M >LUCD

Dow JonesMay 13 20:06

Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0

BenzingaMay 13 20:03

Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures

Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures

BenzingaMay 9 20:23

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireMay 9 19:49

Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale

TipRanksMay 7 20:02

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the

PR NewswireMay 7 19:39

Lucid Diagnostics Highlights Promising EsoGuard Study Results

TipRanksMay 3 05:12

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical

PR NewswireMay 2 20:35

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication fur

PR NewswireMay 2 19:49

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings

BenzingaApr 30 04:31

Lucid Diagnostics Partners With the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 29 20:47

Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses

TipRanksApr 15 17:15

Needham: Reiterates Lucid Diagnostics (LUCD.US) rating and adjusted from buy to buy rating, target price is $2.50.

Needham: Reiterates Lucid Diagnostics (LUCD.US) rating and adjusted from buy to buy rating, target price is $2.50.

Zhitong FinanceApr 12 16:40

Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path

TipRanksApr 12 04:45

Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)

TipRanksApr 11 01:50

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 8 20:30